AGILE is a platform trial for early-phase evaluation of new treatments for SARS-CoV-2 infection. The trial platform is a collaboration led by the University of Liverpool, working with the Southampton Clinical Trials Unit, the Liverpool School of Tropical Medicine, the MRC Biostatistics Unit at the University of Cambridge and the National Institute for Health and Care Research (NIHR) Clinical Research Facilities. The AGILE platform is funded by the Medical Research Council, and the Wellcome Trust, with additional funding for specific candidate evaluations from the pharmaceutical industry and Unitaid. The Chief Investigator of the trial is Saye Hock Khoo.

View More On
Top Bottom